The effectiveness of RCB (Residual Cancer Burden) as a prognostic marker in patients with residual tumors is 32% and ranges from 22% for HR+/HER2− breast cancers to 44% for HR−/HER2+ breast cancers [4]. Here, ERBB2 is linked to cancer.